Isis Earns $10M Biogen Milestone

Isis Pharmaceuticals, Inc. has earned a $10 million milestone payment from Biogen associated with the validation of an undisclosed target to treat a neurological disorder. This is the ninth program to advance under the strategic alliance, which includes four drugs in development to treat neurological and neuromuscular disorders. To date, Isis has earned $329 million in payments from Biogen. 
 
“Together with Biogen, we have made significant progress advancing multiple programs.  In our pipeline, we have four drugs in development with Biogen, including ISIS-SMN_Rx, ISIS-DMPK-2.5_Rx and two drugs to undisclosed targets.  In addition, we have a number of earlier stage programs, like this one, that we will be advancing this year,” said B. Lynne Parshall, chief operating officer at Isis Pharmaceuticals.